VeriChip Successors To Be 510(k)-Exempt, Special Controls Guidance Issued
This article was originally published in The Gray Sheet
Executive Summary
Implantable radiofrequency transponder systems for patient identification and health information will be premarket-exempt but subject to special controls, FDA explains in a final rule that takes effect Jan. 10
You may also be interested in...
ECRI Urges FDA To Host More Workshops On Device Bar-Coding Feasibility
Additional workshops between FDA and stakeholders on device bar-coding feasibility are warranted while the agency investigates mandating bar-coding for devices, according to an 1ECRI white paper
ECRI Urges FDA To Host More Workshops On Device Bar-Coding Feasibility
Additional workshops between FDA and stakeholders on device bar-coding feasibility are warranted while the agency investigates mandating bar-coding for devices, according to an 1ECRI white paper
VeriChip Takes On Privacy, HIPAA Concerns In NCVHS Testimony
VeriChip implantable radiofrequency transponders for patient identification and health information retrieval are "HIPAA-friendly," the manufacturer asserts